Home » Pear Therapeutics Receives Expedited Access Pathway Designation
Pear Therapeutics Receives Expedited Access Pathway Designation
Pear Therapeutics received an expedited access pathway designation from the FDA for its reSET-O prescription digital therapeutic device to treat opioid use disorder.
The Smartphone application includes a web interface for clinicians and is intended to treat patients enrolled in outpatient treatment and on buprenorphine opioid replacement therapy.
In randomized clinical trials, reSET-O plus pharmacotherapy improved abstinence and increased program retention.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May